BioSpecifics Technologies

Biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date.

Launch date

1957

Employees

Market cap

Enterprise valuation

$540m (Public information from Oct 2020)

Hempstead New York (HQ)

Date	Investors	Amount	Round
Jan 2003	N/A	N/A	IPO
Oct 2020	Endo Pharmaceuticals Inc	$540m Valuation: $540m	Acquisition
Total Funding		-

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about BioSpecifics Technologies